Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases ...

(Corrects third to last paragraph to say "the erosion from LOEs (loss of exclusivity)", not "from LOEs (levels of evidence)") ...

E. Merck KG board of partners has announced the appointment of new CEOs to Merck KGaA’s executive board, aiding its ongoing ...

Germany-based Merck KGaA (OTC:MKGAF) (OTC:MKKGY) reacted to press reports and confirmed advanced discussions with SpringWorks ...

Merck KGaA said it appointed two new members to the executive board for the life science and healthcare business sectors, along with a newly-created chief people officer role. The German ...

Merck's German-listed shares closed down 3.7%. Stamford, Connecticut-based SpringWorks, which listed its shares in New York in 2019, is a commercial-stage biotech firm that develops drugs to treat ...

Germany’s Merck MRK0.81%increase; green up pointing triangle KGaA said it is in advanced talks for a potential acquisition of SpringWorks Therapeutics SWTX-1.98%decrease; red down pointing ...

On Monday, Germany-based Merck KGaA (OTC:MKGAF) (OTC:MKKGY) reacted to press reports and confirmed advanced discussions with SpringWorks Therapeutics Inc (NASDAQ:SWTX), which has a market ...

NEW YORK/FRANKFURT (Reuters) - Merck KGaA, the German healthcare and technology group, said on Monday it is in advanced talks to acquire U.S. cancer and rare diseases drugmaker SpringWorks ...

Merck Germany also confirmed that no legally binding agreement has been entered into. There is no certainty that any transaction will materialize. Furthermore, critical conditions have yet to be met.

Germany's Merck KGaA said it is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical company that specializes in rare diseases and cancer.